Metsera [MTSR] vs BridgeBio Pharma [BBIO] Detailed Stock Comparison
Metsera
NASDAQ
Loading...
BridgeBio Pharma
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Metsera wins in 4 metrics, BridgeBio Pharma wins in 10 metrics, with 0 ties. BridgeBio Pharma appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Metsera | BridgeBio Pharma | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -15.72 | -16.98 | BridgeBio Pharma |
| Price-to-Book Ratio | 7.56 | -5.24 | BridgeBio Pharma |
| Debt-to-Equity Ratio | 0.24 | -1.04 | BridgeBio Pharma |
| PEG Ratio | -0.24 | -0.12 | Metsera |
| EV/EBITDA | -12.84 | -17.51 | BridgeBio Pharma |
| Profit Margin (TTM) | 0.00% | 98.25% | BridgeBio Pharma |
| Operating Margin (TTM) | 0.00% | -120.72% | Metsera |
| Return on Equity | -72.78% | 36.76% | BridgeBio Pharma |
| Return on Assets (TTM) | -46.37% | -41.96% | BridgeBio Pharma |
| Free Cash Flow (TTM) | $-100.08M | $-529.63M | Metsera |
| 1-Year Return | 23.77% | 98.46% | BridgeBio Pharma |
| Price-to-Sales Ratio (TTM) | N/A | 39.80 | N/A |
| Enterprise Value | $2.87B | $10.92B | BridgeBio Pharma |
| EV/Revenue Ratio | N/A | 46.32 | N/A |
| Gross Profit Margin (TTM) | N/A | 96.70% | N/A |
| Revenue per Share (TTM) | $0 | $1 | BridgeBio Pharma |
| Earnings per Share (Diluted) | $-2.93 | $-4.13 | Metsera |
| Beta (Stock Volatility) | N/A | 1.23 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Metsera vs BridgeBio Pharma Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Metsera | 1.90% | 8.25% | -17.82% | 14.37% | 3.63% | 23.77% |
| BridgeBio Pharma | 2.76% | -1.86% | 9.43% | 52.95% | 36.31% | 78.12% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Metsera | 23.77% | 23.77% | 23.77% | 23.77% | 23.77% | 23.77% |
| BridgeBio Pharma | 98.46% | 379.29% | 69.75% | 86.24% | 86.24% | 86.24% |
Performance & Financial Health Analysis: Metsera vs BridgeBio Pharma
| Metric | MTSR | BBIO |
|---|---|---|
| Market Information | ||
| Market Cap | $3.40B | $9.39B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 1,318,430 | 3,620,747 |
| 90 Day Avg. Volume | 1,231,887 | 2,736,729 |
| Last Close | $32.80 | $50.23 |
| 52 Week Range | $12.30 - $47.40 | $21.72 - $51.86 |
| % from 52W High | -30.80% | -3.14% |
| All-Time High | $47.40 (Jul 18, 2025) | $73.50 (Feb 08, 2021) |
| % from All-Time High | -30.80% | -31.66% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 50.00% |
| Quarterly Earnings Growth | N/A | 50.00% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.98% |
| Operating Margin (TTM) | 0.00% | -1.21% |
| Return on Equity (TTM) | -0.73% | 0.37% |
| Debt to Equity (MRQ) | 0.24 | -1.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $4.28 | $-9.35 |
| Cash per Share (MRQ) | $5.05 | $3.96 |
| Operating Cash Flow (TTM) | $-177,979,008 | $-655,808,000 |
| Levered Free Cash Flow (TTM) | $-209,127,000 | $-297,633,248 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Metsera vs BridgeBio Pharma
| Metric | MTSR | BBIO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -15.72 | -16.98 |
| Forward P/E | -9.61 | -16.04 |
| PEG Ratio | -0.24 | -0.12 |
| Price to Sales (TTM) | N/A | 39.80 |
| Price to Book (MRQ) | 7.56 | -5.24 |
| Market Capitalization | ||
| Market Capitalization | $3.40B | $9.39B |
| Enterprise Value | $2.87B | $10.92B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 46.32 |
| Enterprise to EBITDA | -12.84 | -17.51 |
| Risk & Other Metrics | ||
| Beta | N/A | 1.23 |
| Book Value per Share (MRQ) | $4.28 | $-9.35 |
Financial Statements Comparison: Metsera vs BridgeBio Pharma
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MTSR | BBIO |
|---|---|---|
| Revenue/Sales | $0 | $116.63M |
| Cost of Goods Sold | N/A | $2.64M |
| Gross Profit | N/A | $113.99M |
| Research & Development | $57.19M | $111.43M |
| Operating Income (EBIT) | $-65.79M | $-103.80M |
| EBITDA | $-60.87M | $-104.46M |
| Pre-Tax Income | $-76.59M | $-169.61M |
| Income Tax | $0 | N/A |
| Net Income (Profit) | $-76.59M | $-169.61M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MTSR | BBIO |
|---|---|---|
| Cash & Equivalents | $588.34M | $540.60M |
| Total Current Assets | $594.74M | $695.17M |
| Total Current Liabilities | $90.74M | $152.11M |
| Long-Term Debt | $514,000 | $1.85B |
| Total Shareholders Equity | $505.39M | $-1.64B |
| Retained Earnings | $-333.73M | $-3.26B |
| Property, Plant & Equipment | $1.27M | $13.86M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MTSR | BBIO |
|---|---|---|
| Operating Cash Flow | $-67.66M | $-215.45M |
| Capital Expenditures | $-7,000 | $0 |
| Free Cash Flow | $-54.35M | $-200.83M |
| Debt Repayment | N/A | $-459.00M |
| Common Stock Repurchase | N/A | $-50.05M |
Short Interest & Institutional Ownership Analysis
| Metric | MTSR | BBIO |
|---|---|---|
| Shares Short | 10.16M | 18.52M |
| Short Ratio | 9.81 | 7.46 |
| Short % of Float | 0.73% | 0.16% |
| Average Daily Volume (10 Day) | 1,318,430 | 3,620,747 |
| Average Daily Volume (90 Day) | 1,231,887 | 2,736,729 |
| Shares Outstanding | 103.04M | 190.04M |
| Float Shares | 64.51M | 151.20M |
| % Held by Insiders | 0.13% | 0.05% |
| % Held by Institutions | 0.84% | 1.02% |
Dividend Analysis & Yield Comparison: Metsera vs BridgeBio Pharma
| Metric | MTSR | BBIO |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |